Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 5/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.36 |
| ▸ | FEN1 | P39748 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.35 |
| ▸ | HAVCR2 | Q8TDQ0 | 1/20 | 0.34 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.33 |
| ▸ | GSK3B | P49841 | 2/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | EP300 | Q09472 | 1/20 | 0.33 |
| ▸ | PDE5A | O76074 | 1/20 | 0.33 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.33 |
| ▸ | CDK4 | P11802 | 1/20 | 0.33 |
| ▸ | CCND1 | P24385 | 1/20 | 0.33 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16508269 | 0.90 | ALOX5AP (0.45) | NPC1JAK2RAB9AALOX5APFEN1 | |
| SCHEMBL16508267 | 0.88 | NPC1 (0.41) | NPC1JAK2RAB9AALOX5APFEN1 | |
| SCHEMBL1703319 | 0.86 | MET (0.40) | METNPC1JAK2RAB9AALOX5AP | |
| SCHEMBL16508272 | 0.85 | CYP17A1 (0.39) | METAURKBHAVCR2CYP17A1GSK3B | |
| SCHEMBL3765201 | 0.76 | ALOX5AP (0.45) | NPC1JAK2RAB9AALOX5APFEN1 | |
| SCHEMBL16508294 | 0.76 | CYP3A4 (0.41) | CYP3A4BRD4 | |
| SCHEMBL16508260 | 0.75 | KIT (0.40) | ALOX5APFEN1HAVCR2CYP17A1GSK3B | |
| SCHEMBL1702697 | 0.74 | CYP3A4 (0.38) | METNPC1JAK2RAB9AALOX5AP | |
| SCHEMBL1702674 | 0.74 | CYP3A4 (0.45) | NPC1JAK2RAB9AALOX5APFEN1 | |
| SCHEMBL1702649 | 0.72 | MET (0.35) | METNPC1JAK2RAB9ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110300103-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | ROCHE PALO ALTO LLC (US) | 2011-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110300103-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | EIF2AK2, ZC3HAV1, IRF3 | MET 3142/4885NPC1 1579/4885JAK2 276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.